摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(tert-butyl)-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-amine | 1151651-69-2

中文名称
——
中文别名
——
英文名称
1-(tert-butyl)-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-amine
英文别名
1-tert-butyl-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine;1-tert-butyl-3-methoxypyrazolo[3,4-d]pyrimidin-4-amine
1-(tert-butyl)-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-amine化学式
CAS
1151651-69-2
化学式
C10H15N5O
mdl
——
分子量
221.262
InChiKey
UEXMKWFIUJLMLI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    389.3±37.0 °C(Predicted)
  • 密度:
    1.32±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    78.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
    摘要:
    A novel 4-aminoindazole sulfonamide hit (13) was identified as a human CCR4 antagonists from testing a focussed library of compounds in the primary GTPcS assay. Replacing the indazole core with a pyrazolopyrimidine, and introduction of a methoxy group adjacent to the sulfonamide substituent, resulted in the identification of pyrazolopyrimidine 37a, which exhibited good binding affinity in the GTPcS assay (pIC(50) = 7.2), low lipophilicity (c logP = 2.2, chromlog D-7.4 = 2.4), high LE (0.41), high solubility (CLND solubility >= 581 mu M), and an excellent PK profile in both the rat (F = 62%) and the dog (F = 100%). Further SAR investigation of the pyrazolopyrimidine suggested that substitution at N1 is tolerated, providing a suitable vector to modulate the properties, and increase the potency in a lead optimisation campaign. (C) 2017 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2017.07.052
  • 作为产物:
    描述:
    5-amino-1-tert-butyl-3-methoxy-1H-pyrazole-4-carbonitrile 、 formamide 反应 2.0h, 以46%的产率得到1-(tert-butyl)-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-4-amine
    参考文献:
    名称:
    Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
    摘要:
    A novel 4-aminoindazole sulfonamide hit (13) was identified as a human CCR4 antagonists from testing a focussed library of compounds in the primary GTPcS assay. Replacing the indazole core with a pyrazolopyrimidine, and introduction of a methoxy group adjacent to the sulfonamide substituent, resulted in the identification of pyrazolopyrimidine 37a, which exhibited good binding affinity in the GTPcS assay (pIC(50) = 7.2), low lipophilicity (c logP = 2.2, chromlog D-7.4 = 2.4), high LE (0.41), high solubility (CLND solubility >= 581 mu M), and an excellent PK profile in both the rat (F = 62%) and the dog (F = 100%). Further SAR investigation of the pyrazolopyrimidine suggested that substitution at N1 is tolerated, providing a suitable vector to modulate the properties, and increase the potency in a lead optimisation campaign. (C) 2017 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2017.07.052
点击查看最新优质反应信息

文献信息

  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    申请人:PFIZER INC.
    公开号:US20190284216A1
    公开(公告)日:2019-09-19
    Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    通式(I)的化合物,或其药用盐,这些化合物的制备方法,含有这些化合物的组合物,以及这些化合物的用途。
  • MODULATION OF PROTEIN TRAFFICKING
    申请人:Bulawa Christine Ellen
    公开号:US20100331297A1
    公开(公告)日:2010-12-30
    Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.
    本发明提供用于治疗或改善由蛋白质运输缺陷所特征的一个或多个疾病的化合物和组合物。一种治疗由蛋白质运输受损所特征的疾病的方法包括向受试者施用或与细胞接触化合物I的药物或其药学上可接受的盐或衍生物。[公式在此]
  • Cyclopentane-based modulators of STING (stimulator of interferon genes)
    申请人:PFIZER INC.
    公开号:US10968242B2
    公开(公告)日:2021-04-06
    Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    通式 (I) 的化合物: 或其药学上可接受的盐、制备这些化合物的工艺、含有这些化合物的组合物以及这些化合物的用途。
  • [EN] MODULATION OF PROTEIN TRAFFICKING<br/>[FR] RÉGULATION DU TRAFIC DE PROTÉINES
    申请人:FOLDRX PHARMACEUTICALS INC
    公开号:WO2009062118A3
    公开(公告)日:2009-12-30
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 西地那非-嘧啶酮杂质 苯甲腈,4-(5-甲基-1,3-噁噻戊环-2-基)-(9CI) 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 羟基氯地那非 磷酸二氢2-甲氧基-5-[(Z)-2-(3,4,5-三甲氧苯基)乙烯基]苯酯 盐(1:?)1,3,5-萘三磺酸,7-[2-[4-[[5-氯-6-甲基-2-(甲磺酰)-4-嘧啶基]氨基]苯基]二氮烯基]-,钠 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基(1R,2S,4S)-2,5,7-三羟基-6,11-二羰基-2-(2-羰基丙基)-4-{[2,3,6-三脱氧-4-O-(2,6-二脱氧-α-L-来苏-六吡喃糖基)-3-(二甲氨基)-α-L-来苏-六吡喃糖基]氧代}-1,2,3,4,6,11-六氢四省-1-羧酸酯 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 昔多芬杂质 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 噁庚并[3,4-c]吡啶-3,9-二酮,5-乙基-1,4,5,8-四氢-5-羟基-,(5R)- 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸,3-氰基-4,7-二氢-7-羰基-,甲基酯 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-7-羧酸 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 卡巴地那非 别嘌醇 别嘌呤醇D2 依鲁替尼杂质37